17 results about "Mental retardations" patented technology

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).

Methods of reactivating transcription of a fragile X mental retardation 1 (FMR1) gene and treating FMR1-associated diseases are provided. Compositions and kits for doing same are also provided.

Fragile X Mental Retardation protein (FMRP) is an RNA-binding protein (RBP) that controls translation of select mRNAs. We discovered that endoplasmic reticulum (ER) stress induces phosphorylation of FMRP on a site that is known to enhance translation inhibition of FMRP-bound mRNAs. We show ER stress-induced activation of inositol requiring enzyme-1 (IRE1), an ER-resident stress-sensing kinase / endoribonuclease, leads to FMRP phosphorylation and to suppression of cholesterol efflux from macrophages and apoptotic cell clearance (efferocytosis) by macrophages. Conversely, FMRP-deficiency and pharmacological inhibition of IRE1 kinase activity enhances cholesterol efflux and efferocytosis, reducing atherosclerosis in mice. Our results provide IRE1 inhibition as a promising new therapeutic approach to delaying progression or treating atherosclerosis.

The application discloses a kind of composite nutrient composition and its application in intervention autism and mental retardation, the composite nutrient composition is composed of composite vitamin, mineral, enterobacterium, apple fruit powder and the substance for improving taste;Wherein, the procyanidin B1 content in the apple fruit powder is more than 30mg / kg, the composite nutrient composition of the application can effectively improve the repetitive stereotyped behavior of autistic children, the degree of anxiety, the degree of cognition, and social skills, and effectively improve the intestinal flora imbalance phenomenon of autistic children.It can also effectively improve the cognitive ability of children with mental retardation.

The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

New gelatinase inhibitors, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and / or prophylaxis of conditions wherein inhibition of gelatinases is useful such as epilepsy, schizophrenia, Alzheimer disease, autism (in particular associated to fragile X syndrome), mental retardation, mood disorders such as bipolar disorders, depression, vascular diseases such as ischemic stroke and atherosclerosis, inflammatory diseases such as multiple sclerosis and rheumatoid arthritis, drug addiction, neuropathic pain, lung diseases such as asthma and chronic obstructive pulmonary disease, cancer and sepsis.

The utility model discloses an anti-drop one-piece hospital gown which comprises a hospital gown body, the hospital gown body is a one-piece gown, an invisible zipper is arranged in the middle of the upper half body of the back face of the hospital gown body, trouser legs are arranged on the lower portion of the hospital gown body, a double-head zipper is arranged at the crotch position of the lower portion of the hospital gown body, and drawstrings are arranged on the two sides of the waist position of the hospital gown body. A traditional up-down split type hospital gown is integrally arranged, and the integrated hospital gown body is provided with the invisible zipper, the drawstring and the adhesive tape, so that the integrated hospital gown body is not easy to take off at will when a patient wears the integrated hospital gown body; the hospital gown solves the problem that people suffering from mental retardation, senile dementia or hypophrenia may take off the gown, and prevents the situation that the patient may be exposed in a cold or unsuitable environment due to the fact that the patient takes off the hospital gown body at will.

Benzaza # imgabs0 # derivatives of formula (I), compositions comprising therapeutically effective amounts of these benzaza # imgabs1 # derivatives, and methods of using these derivatives or compositions in the treatment of cognitive impairment associated with central nervous system (CNS) disorders or associated with cognitive impairment risk factors. In particular, the present invention relates to the use of an alpha5-containing GABAA R agonist (e.g., an alpha5-containing GABAA R positive allosteric modulator) in the treatment of cognitive impairment associated with central nervous system (CNS) disorder or having a risk factor associated with cognitive impairment in a subject in need or at risk, the subjects include, but are not limited to, subjects having or at risk of age-related cognitive impairment, mild cognitive impairment (MCI), amnetic MCI (aMCI), age-related memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), proactive AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), or the like. Cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X disorder, Rett syndrome, compulsive behavior and substance addiction associated with cancer treatment. The present invention also relates to the use of [alpha] 5-containing GABAA R agonists (e.g., [alpha] 5-containing GABAA R positive allosteric modulators), as described herein, in the treatment of brain cancer, including brain tumors, e.g., myeloblastoma, and cognitive impairment associated therewith. # imgabs2 #

The application provides application of polycyclic polyisoprenyl acyl phloroglucinol compounds (PPAP) of two different skeleton types in preparation of medicines for relieving / treating neurodegenerative diseases. The application belongs to the technical field of medicines. The hyphenrone A provided by the application is a 1,9-cracked polycyclic polyisoprenyl acyl phloroglucinol compound, and the hyphenrone L is a polycyclic polyisoprenyl acyl phloroglucinol compound with a complex ring system formed by intramolecular [4+2] cyclization of a monocyclic polyisoprenyl acyl phloroglucinol compound. The compound hyphenrone A and the compound hyphenrone L both have the activity of enhancing the voltage-gated T-type calcium channel current, and can be used for preparing medicines for treating neurodegenerative diseases, and in particular, can be used for preparing medicines for relieving and / or treating diseases such as spinocerebellar ataxia, Alzheimer's disease and mental retardation syndrome, and have the clinical application value.

The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, epilepsy, autism spectrum disorders, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention belongs to the field of gene technology, and in particular to KIF11 gene mutants and applications. Specifically disclosed is a nucleic acid comprising the following target fragment, wherein the target fragment has a c.2680C>T mutation compared with the wild-type KIF11 gene. A polypeptide, wherein the polypeptide has a p.Gln894Ter mutation compared with the wild-type KIF11. A gene mutation, wherein the gene mutation has a c.2680C>T mutation compared with the wild-type KIF11 gene. Application of a biological model containing the aforementioned mutation in the preparation of a screening preparation for microcephaly, without chorioretinopathy, lymphedema, or mental retardation. A screening reagent for microcephaly, without chorioretinopathy, lymphedema, or mental retardation, comprising a reagent capable of detecting KIF11 gene mutants. The present invention provides new mutation sites associated with microcephaly, without chorioretinopathy, lymphedema, or mental retardation, provides a new scheme for the diagnosis and treatment of the disease, and also provides related drugs capable of preventing and treating the disease.

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

The invention relates to a compound, in particular to a medicine for treating cranial nerve dysfunction diseases, namely alpha-asarone and an isomer beta-asarone, the molecular formula is C12H16O3, the molecular weight is 208.26, the Chinese name is 2, 4, 5-trimethoxy-1-propenyl benzene, and a preparation prepared from the alpha-asarone and the isomer beta-asarone can be used for treating cranial nerve dysfunction diseases. The pharmaceutical composition is used for treating various memory, cognition, sensory integration and thinking function partial or all deficiency diseases caused by cranial nerve dysfunction, including Alzheimer's disease, dementia, encephalitis sequelae, cerebral palsy, children intellectual development disorder, autism, hyperactivity and the like.

The "Algorithm for personalizing antipsychotic therapy in children and adolescents with behavioral disorders and mental retardation based on pharmacogenetics"

The invention discloses a composition for treating dysgnosia and application thereof. According to the invention, the AAV virus carrying the hCAPZA2 gene is introduced into a CAPZA2 heterozygous knockout or mutated mouse model, and the effectiveness of the AAV virus in the aspects of improving the CAPZA2 expression level, recovering the synaptic function and improving the neural behavior is verified. The invention not only provides a new hope for treating the mental disorder related to the CAPZA2 gene, but also opens up a new direction for the application of gene therapy in neurodevelopment diseases.